Polymorphisms of CYP1A1 I462V and GSTM1 genotypes and lung cancer susceptibility in Mongolian by Fuhou Chang et al.
Title page 
Title:  Polymorphisms of  CYP1A1 I462V and GSTM1 genotypes 
and lung cancer susceptibility in Mongolian 
Corresponding Author: Fu-hou CHANG1 *,  Ph. D. Department of Pharmacology of 
Pharmaceutical College , Inner Mongolia Medical College, Huhhot 010059, P.R. China;Tel: 
008613904717048; E-mail: changfh@live.cn 
Other authors; 
Zhi-xie ZHANG1, Master Degree student, Department of Pharmacology of Pharmaceutical 
College , Inner Mongolia Medical College, Huhhot 010059, P.R. China  
Jia MA1, Department of Pharmacology of Pharmaceutical College , Inner Mongolia Medical 
College, Huhhot 010059, P.R. China  
Jun QI1, Department of Pharmacology of Pharmaceutical College , Inner Mongolia Medical 
College, Huhhot 010059, P.R. China 
Min-jie WANG1, Department of Pharmacology of Pharmaceutical College , Inner Mongolia 
Medical College, Huhhot 010059, P.R. China  
Qin YIN1, Department of Pharmacology of Pharmaceutical College , Inner Mongolia Medical 
College, Huhhot 010059, P.R. China  
Guang Wang2 ,The first Affiliated Hospital of Inner Mongolia Medical College, Huhhot 010059, P. 
R. China, 
Project supported by the National Natural Science Foundation of China (No. 30661021), Natural 
Science Foundation of Inner Mongolia Autonomous region (No. 200607010907) and Doctor 
Initializing Fund Application of Inner Mongolia medical college(No.2005BQ001). 
 
 
  
 
Abstract  Aim To study the genotype of cytochrome P450 1A1(CYP1A1)  
I462V and glutathions S-transferase M1( GSTM1) with the susceptibility of lung 
cancer in Mongolia of China.  Methods Allele-specific and a multiplex PCR were 
employed to identify the genotypes of them in a case-control study of 210 lung cancer 
patients and 210 matched controls. Results The CYP1A1(Val/Val) and GSTM1(-) 
were the risk factor of lung cancer, the OR was 2.56 and 1.89 respectively. The 
relative risk increased to 2.6 – fold when the patients carried with two valine alleles in 
cases of SCC. GSTM1(-) was the risk factor of SCC (OR=2.39) and AC(OR=2.16). 
The light smokers were the risk factor for lung cancer. Conclusion The valine allele 
of CYP1A1 was the risk factor of lung cancer especially for SCC and GSTM1(-) was 
the risk factor of lung cancer and especially for SCC and AC of Mongolian, China. 
There may be a synergetic interaction between CYP1A1 valine allele and GSTM1(-) 
genotypes on the elevated susceptibility of lung cancer. So do those genotypes with 
light smokers.  
Key words polymorphism; genotype; lung cancer; cytochrome P450；glutathione 
S-transferase   
 Abbreviations: SCC, squamous cell carcinoma; AC, adenocarcinoma; SCLC, small 
cell lung cancer; LCLC, large cell lung cancer 
 
Cytochrome P4501A1 (CYP1A1) metabolizes a number of suspected procarcinogens, 
especially, polycyclic aromatic hydrocarbons(PAHs), into highly reactive 
intemediates. These compounds are capable of binding to DNA to form adducts, 
which, if not repaired, may initiate or promote carcinogenesis. Although PAHs are 
ubiquitous in the environment, exposure sources of particular concern include 
smoking, air pollution, diet and certain occupations[1]. A A4889G substitution 
resulting in a Ile462Val exchange in the heme binding region of exon7 was first 
described in 1991 by Hayashi et al. [2]. This polymorphism has been show to correlate 
with inducibility of aryl hydrocarbon hydrolase activity[3]. Lung cancer is one of the 
commonest human neoplasms . Epidemiological studies have shown that squamous 
cell carcinoma is associated with tobacco and alcohol consumption, and is commonest 
in regions where these products are most often consumed. Chemical compounds 
present in tobacco and alcohol undergo metabolic activation by phase 1 enzymes, 
usually the cytochrome P450 enzymes(CYP). CYP catalyse reactions that result in the 
creation of functional groups on their substrates, thus generating the ultimate 
carcinogen. These carcinogens form DNA adducts, leading to genetic damage. The 
glutathione S-transferases consist of a superfamily of enzymes that catalyse the 
reduction by glutathione of several electrophilic substrates, facilitating the excretion 
of these compounds. These compounds are often products of CYP mediated 
metabolism[4]. Tobacco and ethanol, similarly to most environmental toxins, requires 
metabolic activation and subsequent detoxification by a series of enzymes. 
Glutathione S-transferases (GSTs) are phase II xenobiotic metabolizing enzymes that 
catalyze the conjugation of electrophilic compounds with reduced glutathione to 
produce less toxic or readily excretable metabolites. 
Individual variations in the metabolic activation and detoxification of chemical 
carcinogens and genotoxins, such as tobacco and ethanol, are likely to be one of the 
major determinants of inter-individual differences in susceptibility to environmentally 
induced cancers. The genetic constitution seems to play the most important role in this 
context. An increasing number of xenobiotic metabolizing enzymes, such as GSTs 
and CYPs , have been shown to be polymorphic[5].  
A relatively large number of studies have been published on the association of 
CYP1A1 and GSTM1 polymorphisms and lung cancer susceptibility and the findings 
have been inconsistent. Some of the studies have found that there are relationship 
between the polymorphisms of GSTM1 and CYP1A1 Ile/Val genotype[6-8]. Other 
results are opposite [9;3].Although there are some of Chinese populations data[10], but 
there are few data on Mongolian populations. 
We have studied the distribution of CYP1A1 MspI and GSTM1 genotype between the 
Monglolian and Han nationality of Inner Mongolia. We have not found difference 
between them on the distribution of CYP1A1 Msp I and GSTM1 [11]. We also have 
studied the relationship of polymorphisms of CYP1A1 MspI and GSTM1 genotype 
with the susceptibility of lung cancer on the population of Inner Mongolia. We have 
found  the CYP1A1 MspI mutation homozygote and GSTM1 null genotype is the 
risk factor of lung cancer on Inner Mongolia population[12] . In the present study we 
analyzed the polymorphisms of CYP1A1 I462V and GSTM1 genotypes and lung 
cancer susceptibility on Mongolian. We also considered possible effect modification 
by cigarette smoking and alcohol. 
 
Subjects and Methods 
Study subjects and epidemiology information   This case-control study 
consisted of 210 patients suffering from lung cancer and 210 general 
population-selected healthy controls. Lung cancer cases were recruited from patients 
undergoing bronchoscopy at the first affiliated hospital, Inner Mongolia Medical 
College, China. The ages of patients range from 43 to 86, averaging 43±13; and 
controls from 36 to 83, averaging 67 ± 11. At recruitment, each participant was 
personally interviewed to obtain a detailed information about smoking, dietary habits, 
alcohol consumption and demographic characteristics. Controls were individually  
matched to the patients with respect to gender and age, who were selected from 
healthy individuals free of malignancy. They were interviewed using the same 
questionnaire at the time of their admission for the study. All of the patients and 
controls gave their informed consent, and the study was approved by the Ethics 
Committee of the Inner Mongolia Medical College. Each person donated 5 ml of 
whole blood in haparinized tubes, stored in freezer at -80 centigrade.  
 
 
CYP1A1 I462V  genotyping 
  Genomic DNA was isolated from peripheral blood samples of cases and 
controls according to the protocol of Nakachi et al[13]. To detect CYP1A1 I462V 
polymorphism, an allele-specific PCR procedure was developed using two sets of 
primers[14;2]. Each of primers (1A1A ; 5`- GAAGTGTATCGGTGAGACCA-3` 
and 1A1G; 5`-GAAGTGTATCGGTGAGACCG-3`), was used for PCR 
amplification together with another strand of primer ( C53; 
5`-GTAGACAGAGTCTAGGCCTCA-3`). Initial denaturation was carried out at 
94 centigrade  for 10 min, followed by 30 cycles of denaturation at 95 centigrade  
for 1 min, annealing at 65 centigrade for 1 min and extension at 72centigrade for 1 
min and final extension at 72 centigrade for 10 min in thermal cycler （GeneAmp 
PCR System 2400, PERKIN ELMER, Singapore）.  The two resulting PCR 
products were subjected to electrophoreses in a 2% agarose gel and stained with 
ethidium bromide and observed under the ultraviolet light. The products were all 
210pb fragment for the two sets of primers. If the product was shown only when 
the primer 1A1A and C53 were used, not when the primer 1A1G and C53 were 
used, the subject was identified as a homozygote of Ile (Ile/Ile). On the other hand, 
if the product was got only when the primer 1A1G and C53 were used, not when 
the primer 1A1A and C53 were used the subject was identified as a homozygote 
of Val (Val/Val). When the products present in both primers ( 1A1A , C53 and 
1A1G, C53) indicated the heterozygotes of Ile/Val[7].  
 GSTM1 genotyping 
The GSTM1 genotypes were analyzed by a multiplex PCR according to the protocol 
of Arand et al[15]. Briefly genomic DNA  was amplified by using four sets of primers 
GSTM1 (F) 5`- GAACTCCCTGAAAAGCTAAAGC, GSTM1(R) 
5`-GTTGGGCTCAAATATACGGTGG, Beta-globin 
(F)5`-CAACTTCATCCACGTTCACC , ( R)5`-GAAGAGCCAAGGACAGGTAC, 
Initial denaturation was carried out at 95 centigrade for 5 min，followed by 35 cycles 
under the following conditions: denaturation at 95 centigrade  for 1 min，annealing at 
57 centigrade for 1 min，extension at 72 centigrade for 50 sec and final extension at 
72 centigrade for 10 min in thermal cycler (GeneAmp PCR System 2400, PERKIN 
ELMER, Singapore). The PCR products were then subjected to electrophoresis on a 
2.5% agarose gel. The presence of a 268 (Beta-globin) and 215(GSTM1) bps was 
indicative of the GSTM1 genotypes; whereas the absence of the product of GSTM1 
indicated the GSTM1(-) genotype. Beta-globin was used as an internal control.  
Statistical analysis SPSS 11.5 was used to do the statistics and  the Odds Ratio; their 95% 
confidence interval (CI) and p value for the data were calculated.  All data were considered 
significant difference when p< 0.05 . 
 
Results 
The gender , age , histological types, smoking and alcohol status data were 
summarized on Table 1. 42.86% of patients are light smokers who smoked less than 
30 packs per year and 26.19% of patients are heavy smokers who smoked more than 
30 packs per year. Both light smokers and heavy smokers have significant difference 
between the group of control and patient (p<0.001). The light drinkers are those drank 
alcohol liquid (Containing alcohol less than 42%) less than 36 litres per year and the 
heavy drinkers are those drank alcohol liquid more than 36 litres per year. There are 
no significant difference between the control and patients on the gender, age, alcohol 
status.  
 
Table 2 and 3 show the overall distribution of patients and controls by genotypes for 
the  CYP1A1 (Ile/Val) and GSTM1 polymorphism. The mutant homozygous 
CYP1A1(Val/Val) of lung cancer was 15.24% and was two time more than the 
CYP1A1(Val/Val) of control(7.4%). The CYP1A1(Val/Val) genotype of the SCC 
was higher than that of AC and others, it was 22.77 , 7.69 and 9.09%,  respectively. 
The proportion of GSTM1(-) of lung cancer was also higher than that of control, it 
was 56.67 and 40.95%, respectively. The frequency of the GSTM1(-) of the SCC was 
also higher than that of AC and others, it was 62.38, 60.0 and 38.64%, respectively. 
The one who carried with CYP1A1 (Val/Val) genotype, the risk of lung cancer was 
increased , the OR was 2.56 (95%CI: 1.32~4.93). The statistics show significant 
difference (p=0.004). Carried with CYP1A1(Ile/Val), the risk of lung cancer was 
increased, the OR is 1.42(95%CI: 0.89~2.26), but the statistics show no significant 
difference(p=0.142). When stratified according to histology, there was a strong 
association for SCC with an OR of 4.45(95%CI:2.16~9.17) that the patients who 
carried with CYP1A1(Val/Val) genotype. The risk of AC and others who carried with 
CYP1A1 (Val/Val) genotype  were increased, the OR was 1.14 and 1.34 , 
respectively, but the statistics show no significant difference( p=0.805 and 0.621). 
From the table 3,  the presence of at least one Val allele of CYP1A1, the risk of lung 
cancer was increased , the OR was all larger than 1.0.  There were no statistics 
significant difference of them. The risk of lung cancer who carried two Val alleles of 
CYP1A1  was  1.8-fold of the one who carried with one Val allele of CYP1A1. At 
the same condition, the risk of SCC was 2.6-fold. The one who carried with GSTM1(-) 
genotype, the risk of lung cancer was increased , the OR was 1.89(95% CI: 1.28~2.78) 
and statistics show significant difference ( p=0.001).When stratified according to 
histology, there was a strong association for SCC and AC, the OR was 2.39(95%CI: 
1.47~3.89, p=0.000) and 2.16(95%CI: 1.23~3.81, p=0.007), but not others, the OR 
was 0.91( 95%CI: 0.45~1.77, p=0.776). 
The combined effects of CYP1A1(Ile/Val) and GSTM1 genotypes for all lung cancer 
were also analyzed (table 4). The presence of at least one Val allele of CYP1A1 and 
GSTM1(-), the risk of lung cancer was increased, the OR was 4.15(95%CI: 2.02~8.51) 
for one Val allele and GSTM1(-)  and 2.67(95%CI:1.22~5.84) for two Val alleles 
and GSTM1(-), the statistics show significant difference (p=0.000 and 0.012). When 
there was  one Val allele of CYP1A1 and combined another GSTM1(-) genotype, 
the risk of lung cancer was increased more. 
The risk of developing lung cancer in relation to CYP1A1(Ile/Val) and GSTM1 
genotypes and age , smoking  and alcohol drinking was shown in Tab. 5. Mongolian 
has a habit of drinking and most people like to smoke especially for men. Since the 
Val allele of CYP1A1 was very important in the susceptibility of lung cancer not one 
or two, we combined the heterozygous (Ile/Val) and mutant (Val/Val) alleles as a 
single genotype. Individuals who were lighter smokers and carrying the 
CYP1A1(Ile/Val and Val/Val) or GSTM(-) genotype, the risk of lung cancer was 
increased , the OR was 2.04(95%CI: 1.06~3.94) and 2.0(95%CI:1.03~3.89). The 
statistics show significant difference, the p value is 0.045 and 0.04, respectively.  
There was no associations between CYP1A1 and GSTM1 genotypes and increased 
risk in heavy smokers.  
When stratified the association of  risk of lung cancer and the age , CYP1A1(Ile/Val) 
and GSTM1(-) genotypes, an interesting results were found, the individuals who age 
were less than 50 and carrying the CYP1A1(Ile/Val and Val/Val) genotypes, the risk 
of lung cancer was increased, the OR was 6.64(95%CI: 1.97~22.36, p=0.001), but the 
individuals who age during the 51 to 65 and carrying the GSTM1(-) genotypes, the 
risk of lung cancer was increased, the OR is 2.42(95%CI:1.34~4.4, p=0.003). 
Although the OR was all larger than 1.0 of the individuals who was light drinkers or 
heavy drinkers and carrying CYP1A1(Ile/Val and Val/Val) and GSTM1(-), we could 
not find the association of lung cancer and the drinkers (light or heavy) with 
CYP1A1(Ile/Val and Val/Val) genotypes.   
 
Discussion 
In this population –based case-control study of genetic susceptibility to lung cancer, 
the presence of at least one copy of the Val allele of CYP1A1, the risk of lung cancer 
was increased. When combined with the GSTM(-)  genotypes ,the risk increased 
more, from 1.42 of OR for CYP1A1(Ile/Val) to 4.15 of OR for CYP1A1(Ile/Val) and 
GSTM1(-). CYP1A1(Val/Val) and GSTM1(-) was a factor of susceptibility of lung 
cancer of Mongolian. When considered the histological types, the CYP1A1(Val/Val) 
was association with  the SCC  and GSTM1(-) was association with SCC and AC. 
No association  was found between  CYP1A1(Val/Val) and GSTM1(-) with other 
types of  lung cancer. 
Cigarette smoke contains hundreds of constituents that may play a role in 
carcinogenesis. However, only a fraction of smokers will develop lung cancer. 
Individual susceptibility to chemically induced cancer may be partly explained by 
genetic difference in the activation and detoxification of procarcinogen[7]. Marchand 
et al [ 1]. made a pooled analysis of the CYP1A1 exon 7 polymorphism and lung 
cancer and found that the CYP1A1 exon 7 polymorphism may confer an increased 
risk of lung cancer, particularly of SCC, and especially in never – smokers and in 
women. Our result was similar part of theirs. Shi et al [10] summarized the data from 
46 studies on polymorphism of Msp I and exon 7- Val of CYP1A1  and GSTM1 and 
lung cancer risk in Chinese population and found evidence of an association between 
the CYP1A1 variant  and GSTM1 null genotypes and increased risk of lung cancer, 
the results were also similar with us. We have not found the report about the 
Mongolian CYP1A1 and GSTM1 polymorphisms and the relationship with the 
susceptibility of lung cancer. From our research we found that  the risk for mutant 
homozygote (Val/Val) and  heterozygote (Ile/Val) of CYP1A1 exon 7  was 
2.56-fold and 1.42-fold, respectively,  compared with the wild homozygote of 
CYP1A1 exon 7 (Ile/Ile), and that the risk for the GSTM1(-) genotype was 1.89-fold , 
compared with the GSTM1 (+) genotype. No statistics significant difference was 
found between the Ile/Val genotype and Ile/Ile genotype (p=0.142). When considered 
the histological types, the risk of SCC increased 1.72-fold when the individuals with  
Ile/Val genotype of CYP1A1 and 4.45 –fold when the ones with Val/Val genotype of 
CYP1A1, compared with Ile/Ile genotype of CYP1A1. Also no significant difference 
was found between the Ile/Val genotype and Ile/Ile genotype (p=0.066). The risk of 
SCC increased 2.39-fold the individual carrying GSTM1(-) genotype, compared with 
the individual carrying GSTM1(+) genotype, the statistics show significant difference 
(p=0.000). The reason why CYP1A1(Val/Val) genotype has a high risk of lung cancer 
was not known, it may be connect with activity of enzyme of CYP1A1. CYP1A1 is 
an enzyme with AHH activity that exhibits  a three –way distribution in human 
populations with its higher activity shown to be associated with an elevated risk of 
lung cancer. GSTM1 acts to protect the organism from bioactivated  carcinogens,  
and its absence would facilitate the potential carcinogenicity of such agents. The 
intermediates activated by AHH, if not detoxificated by GSTM1 enzyme could 
accumulate the carcinogen and increase the risk of lung cancer[7]. Presenting at least 
one Val allele, the risk of lung cancer was increased.  Individual carrying GSTM1(-)  
and at the same time  when they took the Ile/Val genotypes, the risk of lung cancer  
was 1.6-fold  than that of individual carrying  Val/Val genotypes.  Those results 
indicated that change of metabolic balance including the activation of procarcinogens 
by CYP1A1 and the detoxification by GSTM1 might have multiplicative effects on 
lung cancer.  
The susceptibility of lung cancer may be association to age. There were few articles 
about that [16] and in our result we found an interesting phenomena, the risk of lung 
cancer for the combined variant genotypes( Ile/Val and Val/Val) was 6.64 – fold , 
compared with Ile/Ile genotype when the age was less than 50. The statistics show 
significant difference (p=0.001). When the age was during the 51~65, the risk of lung 
cancer for the GSTM1(-) genotype was 2.24-fold, compared with GSTM1(+) 
genotype. The statistics also show significant difference (p=0.003).  
The smoke tar can regulate up the expression of aromatic hydrocarbon receptor (AHR) 
and CYP1A1 gene at a certain dosage and time. The regulation of smoke tar for the 
expression of AHR was earlier than that of CYP1A1[17]. The action of the smoking on 
the CYP1A1 , the reports were different. Some of the authors reported that there were 
association between light smokers who carried with CYP1A1(Val/Val) genotypes and 
lung cancer[18]. The present data clearly indicates that the one who carried with 
CYP1A1(Val/Val) genotype and were light smokers had a high risk of lung 
cancer( OR=2.14, 95% CI: 1.06 ~3.94, p=0.045). Others of them reported that 
individuals who were heavy smokers and had CYP1A1(Val/Val) genotypes had a 
high risk of lung cancer[ 8;19]. GSTM1(-) , smokers and the association with the risk of 
lung cancer also had a controversial reports. A slight elevation in risk of lung cancer 
in more casual smokers(BI＞400) was observed[8;19] whereas other studies found 
a strong association with a low smoking exposure[18]. The present data had 
shown association the risk of lung cancer who carried with GSTM1(-) and light 
smokers,  the OR was 2.04(95%CI: 1.03～3.89,p=0.04). There were a strong 
association the smoking and lung cancer, some of gene polymorphism may play a 
more important role, such as CYP1A1(Ile/ Val and Val/Val), others may act as a 
secondary role, such as GSTM1(-). The risk of lung cancer was increased the 
individuals carried with CYP1A1(Ile/Val and Val/Val) and were light drinkers or 
heavy drinkers, the OR were all larger than 1, especially for heavy drinkers and 
carrying CYP1A1(Ile/Val and Val/Val) genotypes( OR=1.79, 95%CI: 0.52~6.02), but 
the statistics show no significance(p＞0.05). 
In this study, a strong association was found between the CYP1A1 valine allele and 
GSTM1 (-) with lung cancer in the Mongolian population. Combined genotyping of 
susceptible CYP1A1 valine allele and GSTM1(-) genotypes revealed a higher risk 
than that ascribed to a single susceptible genotype, for example, CYP1A1(Ile/Val, 
Val/Val) and GSTM1(-). Further these data, as given, provide additional evidence that 
some of polymorphic genes are an important determinant in susceptibility to smoking 
induced lung cancer especially light smokers, such as CYP1A1(Ile/Val and Val/Val). 
Drinking alcohol might slightly increase the risk of lung cancer when individuals 
carried with CYP1A1(Ile/Val and Val/Val) and GSTM1(-). These data may also 
support the hypothesis that susceptibility to certain cancer may depend upon 
ethnic-specific gene polymorphisms. On the susceptibility to the lung cancer with the 
CYP1A1 and GSTM1 genotypes depending on the different age may be biased by the 
relatively small number of subjects in the various subgroup. There are many different 
reports about the association of lung cancer and CYP1A1 and GSTM1 gene 
polymorphism, the inconsistency between our results and other Asian populations, 
such as Japanese[9 ], other parts of Chinese[19], might be ascribed to different 
environmental factors and the number of cases. The study suggested that CYP1A1 
(Ile/Val, Val/Val) and GSTM1(-) could be regard as the susceptible factors of lung 
cancer of the Mongolian population. 
Acknowledgement: We think Prof. Tingmao Hu of Inner Mongolia University for 
technical guidance and Teacher Lei Fan of Inner Mongolia Medical College for 
technical assistance. The Project was supported by the National Natural Science 
Foundation of China (No. 30661021), Natural Science Foundation of Inner Mongolia 
Autonomous region (No. 200607010907) and Doctor Initializing Fund Application of 
Inner Mongolia medical college(No.2005BQ001). 
 
Reference 
1 Marchand Le, Guo Chuanfa, Benhamou Simone Bouchardy C, Cascorbi I, Clapper 
ML, et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer 
(United States). Cancer Causes and Control 2003; 14: 339-346 
2 Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer - 
associated Msp1 polymorphisms with amino acid replacement in the heme binding 
region of human cytochrome  P4501A1 gene. J Biochem 1991; 110: 407-411 
3 London SJ, Yuan JM, Coetzee GA, Gao YT, Ross RK, Yu MC. CYP1A1 I462V 
genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. 
Cancer Epidemiology, Biomarkers and Prevention 2000; 9: 987-991 
4 Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic 
polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1(GSTM1), and 
cytochromes P450 IIE1 and P450 II D6 in the susceptibility to head and neck cancer. 
J Clin Pathol 1998; 51: 294-298 
5 Hou SM, Ryberg D, Falt S, Deverill A, Tefre T, Borresen AL, et al. GSTM1 and 
NAT2 polymorphisms in operable and non-operable lung cancer patients. 
Carcinogenesis 2000; 21: 49-54 
6 Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K, et al. 
Association of Ile 462 Val ( Exon) polymorphism of cytochrome P4501A1 with lung 
cancer in Asian population: Further evidence from a case-control study in Okinawa. 
Cancer Epidemiology, Biomarkers and Prevention 1998; 7: 413-417 
7 Chen Senqing, Xue Kaixian, Xu Lin, Ma GT, Wu JZ. Polymorphisms of the 
CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma 
in Chinese population. Mutation Research Genomics, 2001, 458; 41-47 
8  Sobti R.C., Sharma S., Joshi J., Jindal SK., Janmeja A. Genetic polymorphism of 
the CYP1A1, CYE2E1,GSTM1 and GSTT1 genes and lung cancer susceptibility in a 
north Indian population. Molecular and Cellular Biochemistry 2004; 266: 1~9).  
9 Marchand Le, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, et al. 
Association of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer 
suggest cell type specificities to tobacco carcinogens. Cancer Res 1998; 58:4858-4863 
10 Shi XQ, Zhou SH, Wang ZG, Zhou ZC, Wang ZZ. CYP1A1 and GSTM1 
polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. Lung 
Cancer 2008;59: 155-163 
11 Chang FH, Hu TM. Polymorphisms of CYP1A1 gene MspI site in the Mongolian 
and Han nationality populations of Inner Mongolia of China. Chin J Med Genet 2006; 
23: 333- 334 
12 Chang FH, Hu TM, Wang G. Relationship between CYP1A1 and GSTM1 genetic 
polymorphisms and lung cancer susceptibility in population of Inner Mongolia. Chin J 
Lung Cancer 2006; 9: 413-417 
13 Nakachi K, Imai K, Hayashi SI, Watanabl J, Kawajiri K. Genetic susceptibility to 
squamous cell carcinoma of the ling in relation to cigarette smoking dose. Cancer Res 
1991; 51: 5177-5180 
14 Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. PCR detection of an A/G 
polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Research, 1991, 
19(17): 4797 
15 Arand M, Muhlbauer RJ,Hengstler E, Jager E, Fuchs J, Winkler L, et al. A 
multiplex polymerase chain reaction protocol for the simultaneous analysis of the 
glutathion-S-transferase GSTM1 and GSTT1 polumorphism. Anal Biochem 1996; 
236:184-186 
16 Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz D. 
Polymorphisms in CYP1A1,GSTM1,GSTT1 and lung cancer below the age of 45 
years. International Journal of epidemiology, 2003, 32: 60- 63 
17 Chang FH, Hu TM. Influence of smoke tar on mRNA expression of aromatic 
hydrocarbon receptor and cytochrome P4501A1 gene of mice lungs. Chin J Ind Hyg 
Occup Dis 2006; 24: 85-87 
18 Nakachi K, Imai K, Hayashi S, Kawajiri K: Polymorphisms of the CYP1A1 and 
glutathione-S-transferase genes associate with susceptibility to lung cancer in relation 
to cigarette dose in Japanese population. Cancer Res 1993; 53: 2994-2998, chen et al 
19 Song N, Tan W, Xing D, Lin D. CYP1A1 polymorphism and risk of  cancer in 
relation to tobacco smoking: a case-control study in china. Carcinogenesis 2001; 
22:11-1 
 
 
                           1   2   3  4   5   6   7  
 
                
                                
                      
                                                                             
 
 
   
 
 
 
 
                      
 
Fig 1. Analysis of electrophoretogram of PCR products of CYP1A1 exon 7 gene 
1 and 2 , Val/Val homozygote; 3 and 4, Ile/Ile homozygote; 5 and 6, Ile/Val heterozygote; 
7, Size markers 
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Fig.2 The electrophoretogram of the products of PCR of GSTM1 gene and 
Beta-globin 
M：Markers  1，3：GSTM1（-） 2，4：GSTM1（+） 
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Table 1: Frequency distribution of demographic variables for patients and controls 
 
Variables                   Patients (n=210)(%)             Controls (n=210)(%) 
Gender 
 Male                      176(83.81)                         176(83.81) 
 Female                    34(16.19)                           34(16.19) 
 Age(years) 
 Less than 50                19(9.04)                             29(13.81) 
 During 50 to 65             102(48.57)                           112(53.33) 
 Older than 65              89(42.38)                              69(32.86) 
Smoking Status 
 Never                     65(30.95)                             130(61.91) 
 Light Smokers a             90(42.86)  **                           65(30.95) 
 Heavy Smokers b            55(26.19)  **                          15(7.14) 
Drinking Alcohol 
Never                      31(14.76)                              38(18.09) 
Light Drinkers      c         156(74.79)                             153(72.86) 
Heavy Drnkers      d          23(10.95)                              19(9.05) 
 Histological type 
 Squamous cell carcinoma     101(48.10) 
 Adenocarcinoma            65(30.95) 
 Other                     44(20.95) 
 
a less than 30 pack-year,    b  30 or more pack-year,   c less than 36 litres of alcohol(<42%) – year,   
d  36 or more litres of alcohol(<42%)  – year .    
  Two – sided X2 –test,    **p<0.001 
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Table 2 Distribution of CYP1A1 and GSTM1 genotypes of lung cancer and controls 
 
Genotypes                    CYP1A1 (Ile/Val)                        GSTM1 
                   Ile/Ile       Ile/Val       Val/Val        GSTM1 (+)       GSTM1(-) 
 
Control              151(71.9)   44(20.95)     15(7.4)        124(59.05)        86(40.95) 
Lung cancer          126(60.0)   52(24.76)    32(15.24)        91(43.33)       119(56.67) 
SCC                 52(51.49)  26(25.74)     23(22.77)       38(37.62)        63(62.38) 
AC                 44(67.69)   16(24.62)     5(7.69)          26(40.0)         39(60.0) 
Others              30(68.18)   10(22.73)      4(9.09)          27(61.36)       17(38.64) 
 
 
 
Table 3 OR and 95% CI for lung cancer by CYP1A1 and GSTM1 genotypes 
 
       All (219/230)             SCC                 AC               Other 
            OR (95%CI)           OR (95%CI)         OR (95%CI)         OR (95%CI)           
CYP1A1 
Ile/Ile          1                    1                     1                  1 
Ile/Val     1.42(0.89~2.26)      1.72(0.96~3.06)       1.25(0.64~2.42)      1.14(0.52~2.52) 
             p=0.142             p=0.066              p=0.512            p=0.739 
Val/Val     2.56(1.32~4.93)     4.45(2.16~9.17)        1.14(0.39~3.32)      1.34(0.42~4.33) 
             p=0.004*            p=0.000* *              p=0.805           p=0.621 
GSTM1 
GSTM1(+)      1                     1                     1                1 
GSTM1(-)   1.89(1.28~2.78)      2.39(1.47~3.89)        2.16(1.23~3.81)    0.91(0.45~1.77) 
            p=0.001*               p=0.000**              p=0.007 *          p=0.776 
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Table 4 Combined analysis of genotypes of CYP1A1 and GSTM1 in relation to incidence of lung 
cancer 
 
 GSTM1         CYP1A1      Lung cancer        Control      OR (95% CI )    p-value 
                               n  (%)             n (%) 
GSTM1(+)        Ile/Ile          88(41.9)          69(32.86)              1 
GSTM1(+)        Ile/Val         32(15.24)         13(4.76)     0.52(0.25~1.06)     0.07    
GSTM1(+)        Val/Val        4(1.9)             9(5.71)      2.87(0.85~9.71)    0.079 
  
GSTM1(-)         Ile/Ile          63(30.0)          57(27.14)    1.15(0.72~1.86)    0.556 
GSTM1(-)         Ile/Val         12(5.71)          39(20.0)     4.15(2.02~8.51)   0.000** 
GSTM1(-)         Val/Val        11(5.24)          23(9.52)      2.67(1.22~5.84)   0.012* 
 
 
Table 5 Stratification analysis of CYP1A1 and GSTM1 polymorphism in relation to lung cancer by age 
and smoking 
 
Age; Smoking and      Lung cancer         Control          OR(95%CI)         p- value 
 Drinking  status          n (%)             n (%) 
Less than 50            
Ile/Ile                  7(3.33)            31(14.76)              1    
Ile/Val                 12(5.71)            8(3.81)         6.64(1.97~22.36)      0.001 
GSTM1(+)              8(3.81)            22(10.48)               1 
GSTM1(-)              11(5.24)            17(8.1)          1.78(0.59~5.39)       0.306 
During the 51~65 
Ile/Ile                  68(32.38)            52(24.76)               1 
Ile/Val                 34(16.19)            15(7.14)         1.73(0.86~3.51)      0.125 
GSTM1(+)              43(20.48)            53(25.24)               1 
GSTM1(-)               59(28.1)             30(14.28)       2.42(1.34~4.4)       0.003* 
Older than 65 
Ile/Ile                   51(24.28)            68(32.38)               1 
Ile/Val                  38(18.1)             36(17.14)        1.41(0.79~2.52)      0.25 
GSTM1(+)               40(19.05)            49(23.33)               1 
GSTM1(-)                49(23.33)           39(18.57)         1.54(0.85~2.78)     0.153 
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Light smokers 
Ile/Ile                    29(13.81)            32(15.24)               1 
Ile/Val                    61(20.05)           33(15.71)        2.04(1.06~3.94)   0.045* 
GSTM1(+)                27(12.86)            30(14.28)               1 
GSTM1(-)                 63(30.0)             35(16.67)        2.0(1.03~3.89)    0.04* 
Heavy smokers 
Ile/Ile                     34(16.19)            7(3.33)                 1 
Ile/Val                     21(10.0)             8(3.81)          0.54(0.17~1.71)  0.291 
GSTM1(+)                 32(15.24)             9(4.28)                 1 
GSTM1(-)                  23(10.95)            6(2.86)          1.08(0.34~3.45)  0.899 
 
Light Drinkers 
Ile/Ile                      76(36.19)           79(37.62)                 1 
Ile/Val                     80(38.09)            74(35.24)        1.12(0.72~1.76)  0.608 
GSTM1(+)                  73(34.76)            81(38.57)                1 
GSTM1(-)                   83(39.52)            72(34.28)       1.28(0.82~2.0)    0.28 
Heavy Drinkers 
Ile/Ile                       10(4.76)             11(5.24)                 1 
Ile/Val                       13(6.19)             8(3.81)       1.79(0.52~6.02)  0.352 
GSTM1(+)                    11(5.24)            10(4.76)                   1 
GSTM1(-)                    12(5.71)             9(4.28)       1.21(0.36~4.09)  0.757 
 
 
Light smokers:  less than 30 pack-year  
Heavy smokers: 30 or more pack-year 
Light drinkers: less than 36 litres of alcohol(<42%) – year     
Heavy drinkers: 36 or more litres of alcohol(<42%)  – year 
Ile/Val=Ile/Val +Val/Val 
 
